Biogen Inc. (BIIB) Earnings Call Transcript & Summary

February 12, 2025

NASDAQ US Health Care Biotechnology earnings 70 min

Earnings Call Speaker Segments

Tim Power

executive
#1

Thank you, Jennifer, and good morning, everyone, and welcome to the earnings call for Biogen covering both the fourth quarter and the full year of 2024. On this call, we will be sharing forward-looking statements, and those carry risks and uncertainties that could lead actual results to differ materially from what those statements suggest. A comprehensive list of risk factors appears in our SEC filings, and I'd encourage you to take a look at those. You can find our earnings release and other documents related to our results, along with reconciliations between GAAP and non-GAAP results discussed on this call, in the investors' section of biogen.com. Slides have also been posted to our website, and we'll be using them during the call. Joining me today are our President and Chief Executive Officer, Chris Viehbacher, Dr. Priya Singhal, Head of Development, and Mike McDonnell, Chief Financial Officer. We'll offer some opening comments and then move to Q&A. So that we can get through as many questions as possible, we'll kindly ask that you limit yourself to just one question. And with that, I'll hand over to Chris.

Chris Viehbacher

executive
#2

Tim, thanks. Hello, everyone. Before we begin, I want to mention that Mike McDonnell is giving his final quarterly presentation as Biogen's CFO. Mike, this marks, I believe, your 97th quarter serving as CFO of a publicly quoted company, so congratulations on such an incredible career; let me take this moment to express my gratitude. You've been a wonderful partner and teammate, working alongside you has been excellent, and you will be missed. Robin Kramer is here with us as well. I'm also proud that we've filled this role from inside the company; having that caliber of talent in-house fills us with tremendous pride. So, on to Q4. As everyone is aware, our multiple sclerosis franchise has encountered heightened competition. In truth, every one of our priorities centers on the question of how we build a new Biogen. How do we create a fresh phase of growth? Three core priorities guide our focus. First, obviously, are the four products launched during the past year: Alzheimer's, Friedreich's ataxia, depression, and ALS. Every one of these is not just first-in-class but also the first disease-modifying agent in its respective disease. That fills us with pride regarding the innovation Biogen can deliver; yet at the same time, commercially speaking, this presents a major challenge, because when you're a pioneer in a field, the education burden is far larger; we'll return to that subject a bit more shortly. Second, we have genuinely reprioritized the pipeline. Throughout my years, I've certainly found that concentrating on a handful of key projects sits at the heart of business success, and I'm especially thankful to Priya Singhal and Jane Grogan, since both have truly, in my view, cleared out the pipeline—development in Priya's case and research in Jane's case—and the products now sitting there genuinely excite us. Several key developments will begin reading out in 2026. In our view, this portfolio is worth multiple billions of dollars, and we're likely among the few companies able to point to a pipeline whose peak sales could exceed our existing biopharmaceutical business, provided everything obviously reaches the market. If we could move to the. Oh, and third, naturally, is that we've restructured the company while lowering operating expenses—not merely cutting costs for their own sake, but to unlock resources for putting into growth. That's what we keep doing. Our pipeline excites us, and we've also liberated a great deal of cash flow, as you'll see later. And that cash flow is being invested to provide more substrate for growth. Yes, now, Dan, the next slide, please. What we're up against, essentially, is watching our multiple sclerosis product revenue erode. Still, I'm especially pleased that in 2024, sales from our launch products more than made up for the drop in that multiple sclerosis revenue. In fact, if you look at total revenue, it fell by $160 million, and when you factor in that contract manufacturing was down by $247 million, that tells you our core pharma business genuinely grew. That hasn't happened in four years. And near term, that's exactly our mission: making sure revenue can outpace the decline in multiple sclerosis products. That decline is clearly shaped by several things ahead, among them the timing of a Tysabri biosimilar in the U.S. and the timing of Tecfidera generics in Europe. Let's move to the next slide, Dan. So, as I mentioned, we actually have four highly innovative, pioneering products. Leqembi, which we'll discuss in some detail shortly. Skyclarys for Friedreich's ataxia, again, the very first therapy for Friedreich's ataxia. Through essentially medical claims data, we've been able to establish that roughly 4,800 patients exist in the U.S. That's close to what we expected. One complication is that locating these patients is tougher, since you might have a primary care physician in a rural area with just one such patient, and you've got to track that person down, and we're speaking with primary care physicians, speaking with cardiologists, speaking with pediatricians, so for a very narrow patient population, the prescriber base is quite large, but that, of course, sits at the heart of Rare Diseases. I recall years back, when we bought Genzyme while I was at Sanofi, the marketing people said, "Our marketing strategy is searching for needles and haystacks," and that's precisely what Rare Diseases means, and it's something Biogen also excels at. Naturally, these days we have far more technology at our disposal. Tools like AI and genetic testing can help us locate those patients. But by its very nature, it unfortunately won't be a nice smooth quarter-on-quarter progression. Even so, we're especially proud that we've managed to double the number of patients on treatment over the past year. Not all of them are being reimbursed yet. We can get many patients onto the drug and then negotiate with governments, especially in Europe, to secure reimbursement. Once that happens, those patients shift from free goods patients into treatments that actually generate revenue. In every country, there are always a certain number of diagnosed patients who've been waiting for treatment, and those you can pick up fairly easily. A lot of the older individuals have truly been dealing with this condition for 30, 40 years, and those are the people we genuinely need to seek out. Another growth driver we'll see this year involves our anticipation of securing approval for Skyclarys across Latin America. I traveled to Brazil last year, and Latin America has a substantial patient population. Our rollout began in the U.S., then progressed to Europe, and now we're expanding into South America as well as parts of the Middle East. We anticipate Skyclarys will continue delivering consistent, steady growth. Once more, I recognize that modeling this on a quarterly basis will prove challenging for some of you. Zurzuvae had an excellent launch last year and clearly surpassed what we had anticipated. Something that diverged from our expectations was that OB/GYNs turned out to be the primary prescribers; our original targeting had been on psychiatrists who prescribe at high rates. We continue to see some of them, but as the data shows, OB/GYNs account for 80% of prescriptions. This is also a space where you could potentially have more individuals who have ever written a prescription for PPD than you actually have patients. And once again, targeting along with considering multi-channel marketing and commercial strategies is incredibly important. We have submitted our filing in Europe and are hopeful about receiving an approval at some point later this year.

Chris Viehbacher

executive
#3

Qalsody may not bring in much revenue, but it genuinely marks a breakthrough in treating ALS. We've demonstrated for the first time that neurofilament can really help predict, early in development, whether drugs are likely to work or not. That opens the door to accelerating the whole ALS R&D process. So that's something we're especially proud of. The impact on patients is simply extraordinary; so even though our revenue effect isn't big, our effect on patients' lives definitely is. Dan, please go to the next slide. I showed this slide at JPMorgan, and several investors examining that chart said, "This doesn't look like the chart of a small product." We've all spent years in this business looking at countless launch curves, and we all know an accelerating curve is what we hope to see. Still, to my mind, any curve going from lower left to upper right is a good one—unless we're talking about operating expenses. What we've got here is strong, steady quarter-over-quarter progress. Some questions have arisen about the launch outside the U.S. Clearly the ex-U.S. launch is contributing more than what we saw with prior launches in other regions. In part, I think that's because Eisai is extremely strong in Asia, where they're leading that launch, and in part because a single-payer system removes many obstacles we deal with here in the U.S. With a single payer, you don't have to negotiate nearly as much about things like PET scans, MRIs, and infusion beds. That's made progress easier, and it's just as strong in China as in Japan—not necessarily in patient numbers, but we are seeing very strong growth in China; and since that's a cash-pay market, it really demonstrates how much people value Leqembi, so let's go to the next chart, please; now, I mentioned some of those obstacles, and we firmly believe that simplifying things for both patients and physicians will accelerate the launch. And we have several such catalysts. The first has already been achieved; Leqembi IV maintenance now has FDA approval. We now have the first patients reaching the 18-month mark. Their plaque has been cleared. But as the data show, staying on treatment is critical. If you don't, certain types of plaque do come back. And we've shown three-year data proving that patients who remain on treatment do better than those who stop. That's an important point, since our competition actually can't make that claim. It also matters for educating people about the disease. Clearing plaque isn't the whole story. Keeping it cleared is what matters. The second catalyst is really the arrival of blood-based diagnostics. Absolutely, Labcorp and Quest keep reporting growing revenues for these diagnostic tests. The AHEAD 345 study is fully recruited, and we expect to read out in 2028. Here's what I think will actually make the biggest difference: getting FDA approval for some of these diagnostics, supported by data compelling enough that doctors feel comfortable diagnosing a patient without needing a PET scan or a lumbar puncture. Again, this isn't only about making life simpler for the neurologist — we could also see it used more and more to triage patients. About half of the patients who do get in to see a neurologist end up not eligible for treatment, because their disease is already too advanced. If we could triage a portion of those patients, particularly in primary care, then a larger share of the people who do see a neurologist would actually be eligible for treatment. For maintenance, we'd expect the subcutaneous version. Right now our PDUFA date is August 31st. That as well will really make things easier for the patient and the physician, because infusion beds are no longer needed, and patients can take the drug from the comfort of their own home. One big game changer we see ahead is subcutaneous administration for initiation, which we expect in the first half of next year. Obviously, that helps for the same reasons — no infusion beds to deal with, and patients can get it from the comfort of their own home. The AHEAD 345 study is fully recruited. We expect to read out in 2028; this is a landmark study, because here we could see the potential promise of preventing Alzheimer's. We know that before patients show symptoms, plaques have been accumulating in their brains over many, many years. And unfortunately, substantial damage has already happened by the time symptoms appear; so if we can reach patients earlier, we believe we can achieve even better efficacy. And in fact, Priya will soon show, once again, the low tau patients, which serves as a marker for those at an earlier stage. And there we see dramatically improved efficacy compared with just the 27% on the CDR Sum of Boxes demonstrated in the CLARITY study. So next slide, please. So those are the four products. Clearly, we're also looking at our pipeline. I think there are three key areas here to consider. The first is continued investment and commitment to Alzheimer's. We've brought together some of the top leading experts in Alzheimer's from around the world; they're the ones telling us, first, that nobody is really conducting as much research across a broad area of modalities as Biogen. But second, they are extremely excited about the opportunity to reduce tau and the impact that could have on Alzheimer's. Alzheimer's is going to be a core franchise for Biogen for decades to come. Back in September, we saw really encouraging results for dapirolizumab, and the second phase 3 study is already underway. On top of that, litifilimab covers both CLE and SLE, so we've got a solid lupus portfolio taking shape. I'd like to point out something to everybody: while a lot of potential competitors are under observation in phase one and phase two, out of the many, many, many molecules that have entered the clinic, only 3 have ever delivered a positive phase three result. 2 of those are on the market already, and dapirolizumab is the third. So even though lots of things can stir up excitement, genuine conviction arrives only when you actually have phase three data in hand. Even so, that market might be substantial, and it suits Biogen well, because a great deal of what we've picked up in MS can be translated over to lupus. And then, naturally, comes the third space: these autoantibodies. We've got our anti-CD38. We're looking to kick off 3 phase three studies spanning 3 distinct indications — antibody-mediated rejection, the IgAN, the PMN. And the phase two data we have there are really persuasive. The AHEAD 345 study has finished enrolling, and we anticipate a readout in 2028.

Chris Viehbacher

executive
#4

You can never promise anything when it comes to R&D, yet our enthusiasm for felzartamab is especially high, along with what it might accomplish in rare kidney disease. On top of that, a full stage of data announcements lies ahead of us. As more information arrives and confidence and excitement keep building, I believe that becomes what defines Biogen, with people joining us in our enthusiasm for the pipeline. So with that said, I think I'll. Priya, let's keep the R&D story going, and I'll hand things over to you.

Priya Singhal

executive
#5

Thank you, Chris. Our development team at Biogen wrapped up yet another highly productive quarter. Across the company's main strategic focus areas, we hit a number of significant milestones. Let me start with immunology, where — working alongside UCB, as Chris noted — we kicked off the second phase 3 trial of dapirolizumab pegol in SLE. That comes on the heels of the encouraging results from the first phase 3 trial and the presentation of detailed findings as a late breaker at last year's ACR annual meeting. As Chris pointed out, dapirolizumab pegol stands as just the third agent to post a positive global phase 3 result in SLE. On top of that, felzartamab received orphan drug designation in the E.U., covering both solid organ transplantation and IgA nephropathy. In our view, this designation — designed to encourage work on therapies addressing substantial unmet medical need — highlights how felzartamab could emerge as a valuable new option for serious immune-mediated conditions such as AMR, IgAN, and PMN around the world. Turning to rare disease, we kept opening up new markets for Skyclarys in Friedreich's ataxia and Qalsody in SOD1 ALS. Drawing on findings from the positive MOXIe trial of Skyclarys, we secured approval in Chile, and 13 further regulatory submissions are now under review. That includes more filings in Latin America, where decisions are anticipated this year in places like Brazil and Argentina as our global rollout presses on. Equally important, we made major strides toward boosting the value of key portfolio products for patients. In SMA, regulators in the U.S. and E.U. have now accepted filings for high-dose nusinersen, and an FDA decision is expected in September of this year. In Alzheimer's disease, we recently gained FDA approval for a less frequent IV maintenance dosing regimen for Leqembi. That represents both a major step for Leqembi and a substantial advance in how Alzheimer's treatment is evolving overall. Let me quickly walk through why treating now is so urgent and why maintenance matters, drawing on the Leqembi data we've gathered so far. To begin with, the CLARITY AD study stands out because it didn't screen out patients based on tau brain pathology. As a result, we hold placebo-controlled trial data spanning the entire early Alzheimer's disease population, including people with no tau and low tau — the very earliest stages of AD. Within that group, 76% of patients experienced no decline, while 60% demonstrated clinical improvement at 18 months according to CDR sum of boxes. Put simply, for more than three-fourths of early AD patients, the disease held steady, and over half saw their symptoms improve when given Leqembi. Why does this matter? Because the data indicates that patients treated early in the course of their disease may gain a profound benefit, which drives home how important it is to start treatment early. Beyond that, the data bolsters the promise of our ongoing pre-symptomatic AHEAD 3 to 45 trial. Having just explained why starting therapy sooner matters, I want to remind everyone why the recent maintenance IV approval carries just as much weight. The reason is that the data tells us Alzheimer's doesn't halt once plaques are cleared. Notably, earlier findings from the phase two trial of Leqembi along with its open-label extension indicate that stopping therapy leads to Alzheimer's biomarkers building back up, amyloid plaques among them, and, just as significant, a return to the rate of clinical decline seen in the placebo arm. Thanks to a mechanism of action that sets it apart, our view is that Leqembi holds a unique place, since it stands alone among today's disease-modifying Alzheimer's therapies in demonstrating added benefit when treatment continues after plaque reduction. This slide makes clear that three-year data from CLARITY AD and its open-label extension back the possibility of long-term patient benefit, revealing that ongoing Leqembi treatment produced twice the clinical benefit seen at 18 months relative to a matched natural history cohort. Keeping these results in mind, we're collaborating with Eisai to bring patients more options, with the goal of maximizing both convenience and clinical benefit from Leqembi. That effort includes a subcutaneous formulation that could potentially be given at home, adding further to patient choice and convenience. For subcutaneous maintenance dosing, a PDUFA date of August 2025 is now in place. In 2026, next year, we intend to launch subcutaneous dosing for treatment initiation, which we expect will let even more patients begin therapy, and building on the encouraging results we saw among the no or low tau population in CLARITY AD, we keep moving forward with evaluating the AHEAD 3 to 45, assessing Leqembi in people who have amyloid plaque pathology in the brain but haven't yet developed symptoms, which could potentially broaden Leqembi's use further. Shifting to the pipeline, we've talked before about our work to strengthen it, with the aim of rebalancing risk and investing to win in key areas where we expect future growth. Consequently, our development efforts have zeroed in on a narrower set of clinical-stage programs we consider high conviction and well-positioned to produce a steady cadence of pivotal readouts and possible launches. As this slide shows, that includes key late-stage programs capable of delivering innovation that benefits patients in Alzheimer's and immunology. We'll stay disciplined as we keep gauging inflection points for our internal development pipeline, and also as we weigh possible external innovation opportunities that we think can support Biogen's aim of sustainable growth; with that, I'd like to turn the call over to Mike now for a financial update.

Mike McDonnell

executive
#6

Thank you, Priya, and good morning, everybody. Let me start with a few highlights pulled from the results we reported. Revenue totaled $2.5 billion for the quarter, up 3% versus the fourth quarter of 2023. Non-GAAP diluted EPS in the fourth quarter came in at $3.44, which is 17% above the fourth quarter of 2023. Looking at the whole of 2024, total revenue reached $9.7 billion, a decline of 2% compared with 2023, in line with the low single-digit decline we most recently guided to. Non-GAAP diluted EPS for all of 2024 landed at $16.47, 12% above full year 2023, which also sits within the guidance range we gave most recently of $16.10 to $16.60. The EPS growth and operating income expansion we saw in both the fourth quarter and the full year were underpinned by our Fit for Growth and R&D prioritization initiatives. We're happy that this performance let us produce $722 million of free cash flow during the quarter, taking us to $2.7 billion for the full year. That marks an improvement of $1.4 billion over the $1.3 billion generated in 2023. I'll now move to a few remarks about revenue and commercial dynamics in the fourth quarter. Our MS product revenue was down roughly 8% at actual currency and 9% at constant currency relative to the fourth quarter of 2023. The primary driver there was competition in the space, partly offset by some seasonal channel dynamics. Interferons kept feeling the effect of competition as patients moved to higher efficacy therapies, and Tecfidera kept feeling the effect of generic competition around the world. Tysabri has experienced some impact from a biosimilar entrant in Europe. And while no biosimilar has launched in the U.S. yet, we keep seeing competition intensify in the high efficacy class. Vumerity enjoyed higher demand in the quarter and also got a lift from some seasonal channel dynamics. Turning next to our rare disease franchise, it generated revenue of $535 million in the fourth quarter. That amounted to growth of 13% at actual currency and 15% at constant currency versus the fourth quarter of 2023. Global Skyclarys revenue for the fourth quarter was $102 million, up 83% against the fourth quarter of 2023, with the number of patients on therapy nearly doubling. U.S. Skyclarys revenue for the fourth quarter was $71 million; we kept adding patients during the quarter, but revenue was sequentially affected by an inventory build in the third quarter that was drawn down in the fourth quarter, along with some Medicare discount dynamics. Global Spinraza revenue of $421 million in the fourth quarter was up 2% year-over-year, including 6% year-over-year growth in the U.S.; we're encouraged by how this is performing and look forward to a possible future launch of the high-dose option. Zurzuvae brought in roughly $23 million of revenue for the quarter, driven by higher demand, partly offset by channel dynamics. Once again, Leqembi demonstrated consistent quarter-over-quarter expansion, as global in-market sales recorded by Eisai during Q4 came to about $87 million — roughly a 30% rise compared with Q3 of 2024. U.S. in-market sales for Leqembi in Q4 reached $50 million, an increase of approximately 28% over Q3 of 2024. Now I'd like to offer some observations regarding trends across a handful of important expense categories. Non-GAAP cost of sales, measured as a share of revenue, showed a 300 basis point gain in Q4 relative to Q4 of 2023, largely attributable to reduced idle capacity charges. In Q4, non-GAAP core operating expense — that is, R&D plus SG&A — rose 4% versus the prior year, as savings from our R&D prioritization and Fit for Growth efforts enabled us to absorb most of the added spending tied to our launches. Non-GAAP other expense came to $72 million for the quarter, mostly reflecting net interest expense. Non-GAAP diluted EPS for Q4 was $3.44, which represents 17% growth compared with Q4 of 2023. Let me now give a quick update regarding our balance sheet. Thanks to solid operating income, we produced $2.7 billion in free cash flow during 2024. Keep in mind that the scheduling of certain cash tax payments in 2024 also provided a boost to free cash flow. We finished 2024 holding $2.4 billion in cash alongside approximately $3.9 billion in net debt, and we still believe our balance sheet is strong and positions us to keep investing in growth opportunities both internal and external. Now I'll move to our guidance ranges and assumptions for the full year 2025. For full year 2025, we anticipate non-GAAP diluted earnings per share between $15.25 and $16.25. This guidance range, which relies on FX rates as of February 7th, 2025, incorporates a $0.35 EPS headwind from foreign exchange relative to average exchange rates in 2024. Total revenue for 2025 is projected to fall by a mid-single-digit %. The main driver here is a steeper decline in our MS business versus 2024. That pressure on our MS business should stem from possible biosimilar entry for Tysabri in the U.S. this year along with possible generic entry for Tecfidera in certain European markets. We anticipate that continued strong and growing revenue from our new product launches will partially offset this decline. Please note this revenue range also includes a roughly 1% headwind from foreign exchange. In 2025, we expect the impact from Medicare Part D redesign at the total company level to be limited, approximately $50-$100 million; we expect approximately one-third of this impact to be related to Skyclarys, with the remainder coming from MS; on operating expenses, we remain on track to deliver the $1 billion of gross and $800 million of net savings from our Fit for Growth initiative by the end of this year. So with that in mind, for the full year 2025 we're looking at combined non-GAAP R&D plus SG&A landing at roughly $3.9 billion. Since the savings are going to take a while to materialize, we'd anticipate OpEx running higher early in the year. We're also expecting the non-GAAP operating margin percentage to stay fairly level in 2025 versus 2024. Then, turning to the non-operating side of expenses, I'd point out the pieces that make up our non-GAAP other income and expense line. That line captures interest expense tied to our debt along with certain other expenses, partly offset by interest income earned on our cash balances. For the full year 2025, we anticipate other income and expense coming in as a net expense of roughly $180 million to $220 million. And lastly, a few extra things to keep in mind as you build out your models. Just like in prior years, we anticipate the first quarter will face pressure from seasonality, driven by greater discounts and allowances plus channel dynamics in the U.S., and that will mainly hit our MS business. I'd also flag that, regarding Fampyra, we ended the license and collaboration agreement effective January 1, 2025, and as I said a moment ago, our guidance for the current year reflects the stronger dollar now relative to the same point last year. When it comes to modeling, every cent that the euro moves against the U.S. dollar affects revenue by about $15 million. I'd also point you to the current slide, along with our press release, for additional key guidance assumptions. And to wrap up, we're happy to welcome Robin Kramer as Biogen's CFO, after my retirement later this quarter. This orderly transition plan has been underway for quite a while, and I have every confidence that Robin will be an excellent CFO. I'm excited about what's ahead for Biogen and will stay a supporter and shareholder of Biogen in the years ahead. With that, let's now open the call for questions.

Tim Power

executive
#7

All right. Thanks, Mike. Jennifer, can we go to the first question, please?

Salveen Richter

analyst
#8

Thank you for taking my question. At this point, how do you see capacity preference and the likely timing for external BD, and regarding your growth outlook? Please explain how the current pipeline and the assets you might add fit together. Thank you.

Chris Viehbacher

executive
#9

Thank you, Salveen. I believe Mike will provide an update on capacity. As I mentioned, our pipeline makes us very enthusiastic, yet one thing we want to do is keep strengthening it. After many years, I've come to believe a pipeline can never be large enough. To start with, we undertook a significant overhaul of research. My view is that for businesses like ours, acquiring late-stage assets comes at a very high cost, and ideally we want research to serve as our main engine of innovation — both from within and from outside. So we've rebuilt research from the ground up in order to free up both money and people, letting us pursue additional partnerships and in-license assets, especially those that haven't yet reached GLP tox. On top of that, we're examining essentially every stage, including early-phase development. At this point, I suspect Priya would share my assessment that the number of programs in our early-stage development pipeline remains fairly limited. Still, suppose we do identify candidates during phase three — when a phase two result is especially strong, I'd rather not shoulder major risk on those later-stage trials, since costs escalate quickly there. As for buying other companies, we've been shifting toward fresh therapeutic spaces, immunology and rare diseases among them. Should we locate purchases that strengthen where we stand in those areas, we'll pursue them. No specific deal size is our target. Maybe it's a product in late-stage development; maybe it's already in early-stage commercialization. What matters is that the economics work. From where I sit, this business doesn't have to gamble big on buying other companies. Even so, we're constantly scouting. At any given moment, we've usually got somewhere between 15 and 20 projects on our radar. Still, the reality is that you might sift through 100 opportunities before landing on one worth pursuing. Mike, do you want to walk us through capacity?

Mike McDonnell

executive
#10

Right. Salveen, regarding capacity, our balance sheet is still very strong. During the prepared remarks, we noted that we closed out the year holding $2.4 billion in cash. With an EBITDA run rate exceeding $3 billion annually, against $6.3 billion in gross debt and $3.9 billion in net debt, that puts us around roughly two turns gross and one and a half turns net. We felt quite good about free cash flow this year—in 2020, or rather last year, 2024—which came to $2.7 billion. That cash position, then, is going to keep expanding. So considering the limited leverage, the $2.4 billion in cash we hold, plus rising free cash flow, our balance sheet sits in a very strong spot. Like Chris mentioned, we intend to remain highly disciplined and pursue only opportunities that are financially sound, yet we have considerable room to execute a number of smaller deals or possibly one bigger deal, should it genuinely make financial sense.

Chris Viehbacher

executive
#11

Thanks, Mike. Let's go to the next question, please.

Michael Yee

analyst
#12

Thank you. Priya, during your remarks on the Leqembi slide, you noted that blood-based diagnostics potentially represent one of the key advances. From what I gather, that should arrive during this year. Could you explain the significance of this regarding any bottlenecks, and in particular, would it be capable of fully substituting for PET, or what is the actual mechanism, given that diagnostics tend to be somewhat complex? Thanks.

Priya Singhal

executive
#13

Yes, thank you, Mike. Broadly speaking, I believe correctly identifying Alzheimer's disease and verifying amyloid stays extremely important, and it serves as the gateway into this care pathway. So it matters. With anti-amyloid therapies now emerging, the momentum has been remarkable. As Chris said, we currently have tests at a triage-level sort of tier. What remains to be seen is what near-term availability will look like for an in vitro diagnostic cleared by the FDA that could be deployed broadly, be reimbursed as well, and provide physicians and neurologists with confidence to genuinely rely on that result rather than turning to a PET. Our view is that this will probably arrive in the near term. Fujirebio has submitted already. We're aware of a few others, such as C2N and Roche, that are working on these IVDs, or in vitro diagnostics. One submission has already occurred. Fujirebio submitted last year. Typically, we understand the timeline runs roughly six months. The following phase, I think, involves producing data so that payers and other parties feel assured it can sufficiently reflect the Medicare population, which tends to be the wider group; thus concordance matters, and so does reimbursement. Still, we believe this is progressing very rapidly, and we expect a fair number of milestones to take place in the near term.

Tim Power

executive
#14

Thanks, Priya. Let's go to the next question, please, Jennifer.

Tim Anderson

analyst
#15

Thanks. Regarding your spending outlook, you're stating combined R&D and SG&A of $3.9 billion, roughly $200 million below consensus. Revenues likewise come in slightly under consensus, so the two offset one another. What I'd like to know is, in 2025 specifically, how much does the Royalty Pharma deal remove from the R&D line? I realize the aggregate amount they'll fund is $250 million, but what relief does that provide to 2025 R&D? And then, about Royalty Pharma, should we anticipate Biogen pursuing additional off-balance sheet arrangements of this kind with pipeline programs across the coming one to two years? Thank you.

Mike McDonnell

executive
#16

Tim, this is Mike. Regarding the Royalty Pharma transaction, what we currently expect is that the $200 million we'd get in 2025 from Royalty Pharma would be treated as a reduction to R&D expense. So it would reduce that line by a dollar-for-dollar amount. That's factored into our guidance.

Chris Viehbacher

executive
#17

Turning to the well — as far as other transactions go, what those putting up the money receive generally comes by way of royalties, and getting that to pencil out for each product isn't simple. So right now, our view is that this is a single, standalone deal, yet it's a handy template for removing risk and letting the investment be distributed over additional assets. Basically, it amounts to a method for taking more shots on goal.

Tim Power

executive
#18

All right. Thanks, Chris. Let's go to the next one, please.

Brian Abrahams

analyst
#19

Morning, and thanks for taking my question. Regarding Skyclarys, could you share more detail about what you're observing across the U.S. market? Is there any path to speeding up how patients get identified so that revenue can grow substantially there? Or is the expectation that this becomes a product whose growth comes mainly from outside the U.S.? Also, how significant are the reimbursement obstacles internationally?

Chris Viehbacher

executive
#20

Thank you. On the U.S. side, I'd say several inventive methods are already in place. One involves employing AI and scanning social media platforms to locate where patients are. As I've mentioned previously, the pool of possible prescribers is fairly large. What matters is narrowing that pool down by geography and by the kind of physician who makes a visit productive. That's why we've turned to AI. Naturally, any time a therapy for a condition gets developed, diagnosing that condition draws more attention. So one development we're observing is considerably wider adoption of genetic testing. That testing carries a cost, and in the past physicians weren't always eager to order it when no treatment would follow. With Skyclarys now available, though, we're seeing that usage rise. Then lastly, there's multi and omnichannel marketing, which lets us reach physicians and simply teach them what Friedreich's ataxia is. Other ataxias exist as well, and that's precisely where genetic testing matters. Yet when you follow patient journeys, often three, four years pass before someone receives a definitive diagnosis. Many who are younger in particular are simply deemed clumsy for some stretch of time, after which they gradually lose mobility. It takes a while, since plenty of physicians have never even heard of Friedreich's ataxia, as I mentioned, and that's why education is required. I'd say that with today's technology, we possess many tools that didn't exist even 15 years back, yet it remains a matter of finding one patient at a time; we track how many we've found each week. Reimbursement in the U.S. isn't truly a problem. Obstacles do exist. This is an area where Biogen excels. Our team is highly skilled at guiding patients through the reimbursement system; in Europe, I don't believe reimbursement issues are really appearing. Mostly it's about completing the entire process and presenting cost-effectiveness data. Still, the uptake has us quite encouraged. And once uptake occurs, that serves as a solid proof of the medicine's value when talks with reimbursing countries happen. So it will come along gradually. My sense is that right now, across Europe, reimbursement is available in 10 nations, and with each quarter that passes, additional nations will come on board, and the same pattern will hold outside Europe, in Latin America, to give one example.

Tim Power

executive
#21

Go to the next question, please, Jennifer.

Marc Goodman

analyst
#22

Yes, good morning. Could you provide a bit more detail about how Spinraza is performing within the United States and outside it—specifically the trends, the extent to which inventory levels are playing a role, and what's going on with pricing? A little extra insight would be great. Thank you.

Chris Viehbacher

executive
#23

Mike, you can address the inventory topic. Regarding Spinraza, it's an extremely competitive space with a quite restricted patient pool. As a result, you have a gene therapy, an oral treatment, and an intrathecal option all vying for a fairly modest number of patients. In fact, a substantial share of patients remain undiagnosed or untreated. We therefore tend to focus on younger individuals, though there's genuinely a considerably bigger adult population. Reaching those patients closely resembles the same approach I just outlined for Friedreich's ataxia. So that's what we're doing. The fascinating part is, how do you succeed in a market of that kind? All of us have spent our careers in this industry, and we often say, "Fine, a single daily pill wins over two pills per day. A pill wins over a shot." Yet the truth is, with many of these terrible diseases, what counts is efficacy; and that truly is the Spinraza story. The high dose, in my view, will prove significant since you can reach the necessary therapeutic drug levels far more quickly. And with a neurodegenerative condition, that matters enormously; so we'll be able to reduce the loading doses, so to speak, from 4 down to 2, after which you move to 3 injections annually. One point I believe will prove significant is that we're creating a device that should reach the market around, as I recall, 2026, Priya. It's a port that can be placed beneath the skin almost anywhere on the body, though certainly in the abdominal area, for instance. It features tiny catheters that extend to the spinal column. This means you can simply administer the injection directly beneath the skin. That has generated an enormously positive patient reaction. And it could genuinely make intrathecal injections far more comfortable for patients, not only in SMA, but essentially across all the intrathecal products we're working on. I believe that one will prove to be a game changer as we move forward. Mike, would you like to discuss the inventory dynamic?

Mike McDonnell

executive
#24

Yes. Marc, there's nothing we need to flag regarding inventory. We did observe a bit of unevenness when it came to Spinraza revenue across 2024, driven by shipment timing and similar factors beyond the U.S. As for the fourth quarter, with 2% growth globally and 6% in the U.S., there's nothing significant to point to when it comes to inventory or channel dynamics.

Tim Power

executive
#25

Let's go to the next question, please.

Paul Matteis

analyst
#26

Hey there, good morning, and thanks a lot for taking my question. Chris, if you step back at this point, you'd have to be at a stage, I'd imagine, with Zurzuvae, Skyclarys, and lecanemab to some extent, though perhaps the spread of results in that case is somewhat broader. Or at minimum over the coming couple of years, you likely possess fairly solid visibility into how these products could turn out; so I suppose, stepping back, do you believe you can return to sustainable revenue growth given what's in-house and what you can see clearly? Or how crucial, I'd ask, is securing a major upside victory from the pipeline or acquiring growth from outside through BD?

Chris Viehbacher

executive
#27

Okay, so when you add up all the pieces, there's about $4.5 billion in MS revenue still on the table, and profit of roughly $3 billion. Over the coming 5 to 10 years, that's what will weigh on us, because a number of these products actually have strong patient retention — people do well on them and typically stay on them. That means the decline happens more gradually. So that's the issue we're working through. If you look at it, the product with the biggest potential to offset that is unmistakably Leqembi; and on that front, the newer data has been encouraging, I'd say. We're quite confident, honestly, that these catalysts might create an opportunity for growth to speed up somewhat. In Alzheimer's, we genuinely see an enormous need that isn't being met. It slips people's minds that patients die from this condition. Looking at the figures Priya presented, achieving stabilization for 76% of patients on this therapy — that's evidence where we truly ought to be doing more work to show what Leqembi brings to the table in terms of value. That's why we're pursuing several distinct strategies. With Eisai, our partner, the conversations we've had about how to approach this commercially have been, I'd say, very productive. In the beginning, a tremendous amount of work went into simply walking people through care pathways, adverse effects, and reimbursement issues. These days, though, I believe we're able to concentrate far more on the value proposition and on the reasons for treating patients. Expanding the prescriber base strikes me as a massive opportunity. Because of how much effort neurologists had to put in, we'd narrowed our focus to a modest number. Still, with options such as the subcutaneous formulations and maintenance, the chance to reach a wider group is now there. Roughly 13,000 physicians make up the target list, and only a small portion of them are writing prescriptions at present — so plenty of room remains. Skyclarys is going to keep expanding, just as we've indicated. Zurzuvae is definitely a fascinating one. In baseball language, I'd describe it as sort of a double in the U.S. My sense is that over in Europe, only a smaller set of nations will wind up reimbursing for this therapy. I believe there's a great deal more we could still accomplish. The real growth story, in my view, shows up once pipeline programs start coming through, because as the MS business contracts and newer products carry more weight, and then suddenly you add a pipeline candidate on top of all that; and the wonderful thing about Biogen is that a billion dollars truly transforms the situation. So it doesn't take much on our end to create a real effect on growth. That means, Paul, it's really everything I just mentioned working together; a growing share of our revenue will come from those new products, and the pipeline simply adds to it.

Tim Power

executive
#28

Thanks, Chris. Let's go to the next question, please.

Umer Raffat

analyst
#29

Hey, everyone. Appreciate you fitting me in. I also want to express my gratitude to Mike for everything you've done to assist me throughout this period; and Tim, welcome aboard. There are two things I'd like to ask today, if that's alright. The first one is probably directed at Priya. Priya, suppose Lilly were to succeed with TRAILBLAZER-ALZ 3 in preclinical on the progression endpoint — what impact would that have on the way you're considering speeding up the timeline for AHEAD 3 to 45, and on how comfortable you'd be with the endpoint utilized in that study? Then second, Chris, perhaps something more macro. Looking at where the valuation sits right now, roughly $20 billion in market cap compared with what was paid for Reata and the balance sheet capacity that exists for another deal on the horizon, my sense is the market is nearly pricing in a belief that the M&A decisions made over the last couple of years weren't what people had anticipated, or maybe expectations had been set higher. So how are you processing that whole picture, and what lessons are you drawing from it as you think about deploying more capital? Because doing another $10 billion deal would be a pretty major step.

Priya Singhal

executive
#30

I'll jump in first. Thank you, Umer. Overall, I'd say we're still enthusiastic, as I mentioned during my prepared remarks, about what AHEAD 3 to 45 could offer. As a reminder, enrollment wrapped up last year. The therapy runs for four years, so our expectation — and Eisai recently did reaffirm the outcome anticipated in 2028. That being said, we always keep and continuously assess the option of getting readouts sooner or making earlier cuts, and we stay in very close contact with regulators such as the FDA on this matter, and everything there is moving along nicely; so that covers the acceleration aspect. What I think matters most here is how the trial was designed; it's highly tailored to amyloid load, and as you're aware, there are two sister trials — one involving a lower amyloid load, which is AHEAD 3, and then 4 to 5, involving a higher amyloid load; in AHEAD 3, we have a biomarker outcome, essentially amyloid clearance; however, in 4 to 5, where patients carry a greater amyloid burden, we're evaluating a highly important endpoint known as the PACC5, which stands for the preclinical Alzheimer's cognition composite. That includes pieces like memory, the intelligence test, MMSE, plus other elements; and it's meant to be quite sensitive and specific for preclinical AD. TRAILBLAZER-ALZ 3 uses different outcomes, such as CDR global score, and additionally incorporates a time-to-event approach. So I think we'll hold off until we see more about how that plays out; but our confidence in this trial's design and what it can reveal regarding preventing or slowing the onset of Alzheimer's disease is quite strong. Chris, over to you.

Chris Viehbacher

executive
#31

Right, Umer, there's a human element at play in all this, isn't there? Something I've noticed throughout my career is that how eager you are to pursue big acquisitions tends to move in the opposite direction from how confident you feel about the assets already sitting in your pipeline. So when you believe there isn't much in your pipeline, that's precisely when you're inclined to spend more on outside opportunities. Logical or not, that pattern has generally described where you've been. And honestly, when I arrived at Biogen, we had a habit of chasing the toughest problems out there — ones where the fundamental disease biology remained a mystery, and where we lacked phase two data that could genuinely tell us where things stood heading into phase three. Back then, the mindset is basically: when you lack clarity about your assets, you end up wanting to dig into everything. Fast forward two years to where we are now, and my take is that Priya — DELI included — has truly swept away a large portion of our pipeline that either had no path to reaching the market or, even if it launched, would have delivered minimal impact. With what's left, along with the extra data we've gathered since, our confidence is much stronger. Take dapirolizumab, which now has a phase three, and litifilimab has moved forward. Looking at the HI-Bio deal, we view it as quite a game-changer for our pipeline, since it represents precisely the kind of thing we want to pursue more often — phase 2 data that provides a reasonable degree of confidence heading into phase 3, while acknowledging that nothing in R&D is ever guaranteed. So where things stand is that we'd be open to completing additional transactions similar to HI-Bio. The Reata deal is one we genuinely appreciate. Perhaps opinions on the street differed, but my sense is that the street hasn't fully grasped the way certain rare diseases actually operate. Our belief over the long run is that Skyclarys will become a meaningful product. I'd say that product is already a big one. Suppose we came across another Reata — a company with something close to hitting the market — and the acquisition price worked out such that our shareholders got a return. In that case, we'd go ahead. That said, I believe one piece of the difficulty is that those selling companies haven't really absorbed all the pressures bearing down on this industry. For our industry, the IRA effectively shortens patent life. On top of that, pricing pressure comes at us from all over the globe. So the commercial return you can get from any single molecule these days falls short of what it was just five years back. Even so, I'm not really seeing much movement in what buyers are willing to pay, whether we're talking about premiums or straight prices. There's always some distance between what you know well and what you end up buying. So for now, my view is that we'll continue evaluating opportunities. Should another company like Reata show up, chances are we'd go after it. We aren't in a big rush to make one deal that would eat up every bit of our cash flow, because I think there's desire on our part to build the pipeline through several assets. If we managed to do more deals along the lines of HI-Bio, that would probably be the ideal zone for us. We've pretty much concluded that we can manage fine as things are until the pipeline grows further, so we don't feel any strong pressure to move. Still, I believe it's every leader's responsibility in this company to keep scanning externally for additional sources of innovation. But as I mentioned, I'm feeling quite optimistic about Biogen's position. Whether our share price shows it or not, I'm definitely not the only one who believes the share price fails to capture where we stand, and I think that stems from a great deal of uncertainty surrounding our sector. Even so, we're staying focused and delivering on our launches, ensuring these products reach the market, and seeking out shareholder value-enhancing transactions that might be possible at essentially any point along the value chain.

Tim Power

executive
#32

Let's go to the next one, please, Jennifer.

Chris Schott

analyst
#33

Excellent. I really appreciate you asking that. I'd like to return to the operating expense baseline. I'm aware that the organization is finishing up its Fit for Growth initiative, and the Royalty Pharma transaction introduces a few variables; however, when we look ahead at the P&L, would roughly $3.9 billion be a reasonable approximate figure to use as Biogen's OpEx base going forward? Or could you provide any additional insight regarding how we should view margin improvement over the coming years? Thank you.

Chris Viehbacher

executive
#34

Yes, Chris, I'd agree with that. Our Fit for Growth initiative was set up to bring operating expenses down to a point where they can sustain what we expect from revenue. And as 2025 comes to a close and we move into later years, clearly, whenever we've got launches to back and similar priorities, we'll have to put appropriate investment behind them. Still, I believe your characterization is accurate, and the program will wrap up by the close of this year, with that $3.9 billion base rate serving as a solid figure for your baseline model. Yes. Of course, with business development, each deal you sign can add fresh R&D spending. Still, I think we've demonstrated a focus on prioritization; we've in fact halted quite a few programs internally, and that builds the financial headroom to pull other assets in. A major issue with business development tends to be that the R&D budget is already maxed out, leaving no space for new items. We're genuinely making some of those tough calls. That applies to research as well. Our research budget has been cut substantially, yet the aim wasn't simply to trim cost. The aim was to have a different mix within it. Through prioritization, we can pursue business development while avoiding any rise in our total spending. That's at least what we've managed to achieve up to now.

Tim Power

executive
#35

I realize our time is almost up. Perhaps we can fit in a final couple. Let's move on to the following question.

Evan Seigerman

analyst
#36

Hey, everyone. Thanks a lot for taking my question. Mike, congratulations on retiring. You'll be missed. Robin, I'm very excited to work with you. And Tim, congratulations on your first earnings call at Biogen. I managed to fit all that in. I'd like to briefly address GLP-1 use in Alzheimer's disease. Novo Nordisk has discussed the Evoke trial quite a bit — high risk, high reward. If it succeeds, what then, and could this change the standard of care for Alzheimer's prevention in some way? Priya, perhaps we'd appreciate your perspective on that. Thank you.

Priya Singhal

executive
#37

Yes. Thanks, Evan. That's a fascinating hypothesis, and it has support from certain preclinical data plus a meta-analysis examining all-cause dementia and then certain subsets that also included Alzheimer's disease, and the scientific rationale underlying it really involves considering how glucose metabolism, or its regulation, may influence neuroinflammation, vascular health, all of those things, and add to a better brain health picture, and I believe that deserves exploration. I mean, we should keep in mind that certain randomized controlled trials have already failed in this area, with pioglitazone and then, in fact, Novo with liraglutide, a small trial, 72 subjects, the ELAD trial; their primary endpoints were not met. Having said that, I think we're eager to see the outcomes. What I believe is truly essential to keep in mind is that when you take on something like Alzheimer's disease, you must take on the central pathology. We also know the central pathology isn't an overnight buildup but accumulates across years; therefore, we remain convinced that an anti-amyloid agent such as Leqembi that genuinely targets plaque yet keeps addressing soluble toxic species following plaque clearance will have a significant part to play. So I think we're anticipating the results of Evoke and Evoke Plus, just like everyone else. But I think we remain convinced that Leqembi is going to play, and keep playing, a significant part.

Tim Power

executive
#38

Great. Let's go to our last one, please.

Phil Nadeau

analyst
#39

Morning. Appreciate you squeezing us in. I'd like to extend our congrats to Mike, Robin, and Tim regarding their new roles. To examine Leqembi's near-term path in greater detail, during Q4, sales rose 30%, yet the amount recognized was just $1 million higher. Could you explain what's driving that? Did one-time items play a role, or is there higher spending we ought to factor into 2025? Turning to 2025 patterns, the 2024 expansion came mostly — not completely, but mostly — from outside the U.S. Can that be repeated in 2025, or have those markets already yielded their easiest gains? Thanks.

Chris Viehbacher

executive
#40

Well, I'd say Leqembi within the U.S. definitely climbed 200% in Q4 versus Q1. So meaningful growth is happening in the U.S.. True, markets outside the U.S. have been robust too; my view is it's a combination of both. For 2025, assuming nothing changes, our best estimate is that trends largely carry on as they are. IV maintenance might bring some pickup, though we won't have the subcutaneous version for maintenance until essentially the final stretch of the year. Blood-based diagnostics might contribute, yet everyone recognizes that getting diagnostics accepted and reimbursed takes time; so my expectation is solid, consistent gains each quarter. Donanemab hasn't had much effect so far and may matter eventually, but I believe they face the very same challenges we do. The key point, as I mentioned, is broadening the prescriber base. The real focus should be on treatment benefits and launching these new formulations. So I expect ongoing improvement. We still firmly believe Alzheimer's could become a major market, which is why our investments span tau as well as other modalities. The unmet need is extraordinary. 500,000 new patients annually; it ranks among the top causes of death, particularly for those over 65, yet it's even a top 10 cause of death across the general population; plus there's the toll this takes on families. So the unmet need is enormous. Clearly, near term, capacity limits remain significant, though I think we've achieved considerable headway in easing some of them; and now, with new formulations like SubQ and blood-based diagnosis, we have a chance to speed up our growth, I'd say, across the coming two to three years.

Mike McDonnell

executive
#41

And Phil, regarding those figures, I want to repeat a point from our prepared comments: worldwide in-market sales for Leqembi during Q4 came to $87 million, which represents roughly a 30% rise compared with Q3 of 2024 in the U.S. Out of that $87 million total, $50 million came from the U.S., marking an increase of approximately 28% quarter over quarter.

Tim Power

executive
#42

Appreciate it, Mike, and I want to thank all of you for spending part of your day with us. If anything comes up afterward, the investor relations group will be around to help with those questions later today. Thanks.

Operator

operator
#43

This does conclude today's conference. We thank you for your participation.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Biogen Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.

Get the API View API docs →

This call discussed

For developers and AI pipelines

Programmatic access to Biogen Inc. earnings transcripts and 132,000+ others is available through the EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments, full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.

More tools for stock research

OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Biogen Inc. or any ticker on your watchlist.

StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.